BiogenIdec

FirstWord Lists – The drugs that will shape 2015
FirstWord Lists – The drugs that will shape 2015
First Word Pharma
Harvoni
Viekira Pak
Gilead Sciences
AbbVie
alirocumab
evolocumab
Amgen
Regeneron
Sanofi
Opdivo
Keytruda
Merck
Bristol-Myers Squibb
Novartis
CTL019
Zarxio
Pfizer
palbociclib
Saxenda
Trulicity
Afrezza
MannKind
Eli Lilly
Novo Nordisk
LCZ696
Toujeo
Breo Ellipta
GED-0301
Celgene
BiogenIdec
Flag link:
Could This 1 Lawsuit Destroy Biogen Idec Stock?
Could This 1 Lawsuit Destroy Biogen Idec Stock?
Motley Fool
BiogenIdec
Tecfidera
MS
multiple sclerosis
patents
Actavis
Mylan
Synthon Pharmaceuticals
Novartis
Hexal
Sanofi
Zentiva
Flag link:
What to Watch for in Biotech Earnings This Week
What to Watch for in Biotech Earnings This Week
Motley Fool
biotech
earnings
Gilead Sciences
Celgene
Amgen
BiogenIdec
Flag link:
Between RX and A Hard Place: Biotechs Flash Warnings
Between RX and A Hard Place: Biotechs Flash Warnings
Investors.com
Alexion
BiogenIdec
Santarus
Regeneron
Flag link:
Biogen Gains A Leg Up In Fiercely Competitive MS Field
Biogen Gains A Leg Up In Fiercely Competitive MS Field
Seeking Alpha
BiogenIdec
MS
multiple sclerosis
Tecfidera
Flag link:
Biotech Stocks Under Pressures, Focus On IPOs
Biotech Stocks Under Pressures, Focus On IPOs
Property Mentor Group
IPOs
Sequenom
Invovio
Aeterna Zentaris
Sarepta
InterMune
Cryolife
BiogenIdec
Boston Scientific
Varian Medical
Warner Chilcott
Flag link:
GlaxoSmithKline, Biogen Idec strike antibody deals with biotech startup Adimab
GlaxoSmithKline, Biogen Idec strike antibody deals with biotech startup Adimab
Fierce Biotech
Adimab
GSK
BiogenIdec
antibody discovery
Flag link:
A Look at Four Major Players in Multiple Sclerosis Treatments
A Look at Four Major Players in Multiple Sclerosis Treatments
Motley Fool
MS
multiple sclerosis
XenoPort
BiogenIdec
Novartis
Alkermes
Tecfidera
Gilenya
ALKS 7106
Flag link:
Biogen Idec Earnings Preview: Get Ahead of the Analysts
Biogen Idec Earnings Preview: Get Ahead of the Analysts
Wall St. Cheat Sheet
BiogenIdec
earnings
Flag link:
Alkermes Adds Multiple Sclerosis Pill To Expanding Pipeline
Alkermes Adds Multiple Sclerosis Pill To Expanding Pipeline
TheStreet.com
Alkermes
multiple sclerosis
MS
monomethyl fumarate
Tecfidera
BiogenIdec
Flag link:
3 Bio Companies Facing The Patent Cliff
3 Bio Companies Facing The Patent Cliff
Seeking Alpha
patents
patent cliff
AbbVie
BiogenIdec
Eisai
JNJ
Eli Lilly
Novartis
Sanofi
Roche
Flag link:
7 Upcoming Biotech Catalysts For Year-End 2012 And Early 2013
7 Upcoming Biotech Catalysts For Year-End 2012 And Early 2013
Seeking Alpha
Alexza
BiogenIdec
Celsion
Celgene
Sanofi
JNJ
Threshold Pharmaceuticals
Flag link:
Biogen's New Hemophilia Drug Could Replace Pfizer's Old One
Biogen's New Hemophilia Drug Could Replace Pfizer's Old One
Forbes
hemophilia
Pfizer
BiogenIdec
factor IX
BeneFix
Flag link:
Battle Lines Drawn in the MS Market
Battle Lines Drawn in the MS Market
Motley Fool
multiple sclerosis
MS
BiogenIdec
BG-12
Sanofi
Aubagio
Gilenya
Novartis
Flag link:
Multiple sclerosis drugs seen gaining traction
Multiple sclerosis drugs seen gaining traction
Marketwatch
MS
multiple sclerosis
BiogenIdec
BG-12
Aubagio
Sanofi
Flag link:
Is Biogen Too Good To Be True?
Is Biogen Too Good To Be True?
Seeking Alpha
BiogenIdec
Avonex
Tysabri
Fampyra
Fumaderm
Flag link:
Biogen, Shire, Novo top pharma ranking of shareholder value
Biogen, Shire, Novo top pharma ranking of shareholder value
Fierce Pharma
BiogenIdec
Shire
Novo Nordisk
Flag link:
Rituxan And Its Biosimilar Competitors
Rituxan And Its Biosimilar Competitors
Seeking Alpha
Rituxan
BiogenIdec
Halozyme
Hospira
iBio
Lonza
Merck
Novartis
Pfizer
Roche
Spectrum Pharmaceuticals
cancer
Viropro
Teva Pharmaceuticals
Flag link:
Biogen Second-Quarter Profit Rises As Avonex Sales Increase
Biogen Second-Quarter Profit Rises As Avonex Sales Increase
Bloomberg
earnings
BiogenIdec
Flag link:
Earnings Preview: Biogen
Earnings Preview: Biogen
Yahoo/Zacks
BiogenIdec
earnings
Flag link:

Pages